FDA Approves RASONQUE — Revolution Medicines, Inc.

Revolution Medicines today achieved a significant strategic milestone with the FDA approval of NDA220910 for DARAXONRASIB (oral), a development that broadens the company's portfolio and bolsters its position in the rapidly evolving non-small cell lung cancer market. This expansion of approved pipeline assets underscores Revolution’s ability to rapidly translate scientific innovation into commercial pharmaceutical products.